NEW YORK, NY--(Marketwire - Mar 14, 2013) - Nuvilex, Inc. (OTCQB: [ NVLX ]), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, has established a subsidiary in the Medical Marijuana industry.

Stock House Group, a full service investment relations firm focused on research, awareness and content development takes a look into the company that's giving the Medical Marijuana sector another biotech that will help to legitimize the drug for medicinal purposes.

In the U.S., there has always been a raised eyebrow in the room when it comes to using marijuana for medicinal purposes, but it's slowly eroding with more and more states passing legislation in favor of the use of marijuana for health reasons.

Make no mistake about it, medical marijuana is big business and prescription cannabis is now available in 18 states, the nation's capital, and eleven more states are considering legalizing the drug medically as well. The numbers are staggering -- in this country, we're talking about a $1.7-billion medical marijuana market and growing rapidly.

Marijuana's reputation is well documented and the once raised eyebrow at the mere mention of passing laws allowing its use is now starting to lower a bit as positive press defines the amazing benefits that can be realized from the drug. It will be the research and studies done by biotechnology companies like Nuvilex Inc. (OTCQB: [ NVLX ]) subsidiary, Medical Marijuana Sciences, Inc. and Cannabis Science, Inc. that helps change the image of marijuana from solely a drug to a medicine.

When serious diseases like brain, pancreatic, and other forms of cancer are diagnosed, patients aren't too concerned where a cure comes from, so Nuvilex, Cannabis Science and other biotechs are hard at work discovering the medical advantages of marijuana.

Read the full Feature News Article at[ www.stockhousegroup.com/features ]

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEO's to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we're building a library of Research to assist Investors in their due diligence on micro, small and large cap stocks.